SecBot SecBot
PRESS-RELEASE ·Filed Mar 5, 2026

IMTX

https://immatics.com/
NEUTRAL
Impact 5/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

The stock reaction may be muted due to the expected nature of the revenue decline and strong cash position. Traders should focus on upcoming clinical catalysts in 2026, particularly data readouts for IMA203CD8 and IMA402, which could drive sentiment despite current financial losses.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$10.15
T+0 close · Mar 5, 2026 · via day close
Latest settled
+9.75%
T+60 · $11.14
Vs SPY
−1.55%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 5 $10.15entry
  2. T+1 · 9mo ago −2.86%α −1.54% · $9.86
  3. T+5 · 8mo ago −7.29%α −5.05% · $9.41
  4. T+20 · 8mo ago +1.97%α +5.76% · $10.35
  5. T+60 · 6mo ago +9.75%α −1.55% · $11.14
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Immatics reported full-year 2025 financial results with a significant revenue decline to $56.8 million and a net loss of $230.8 million, driven by the prior year's one-time collaboration revenue. The company maintains a strong cash position of $551.4 million, extending its runway into 2028, and continues to advance its PRAME-targeted oncology pipeline with key milestones expected in 2026 and 2027, including pivotal data readouts and BLA submission for anzu-cel in melanoma.

Key Financial Metrics

Revenue
$56.8M
-69.0% YoY
EPS
$-1.61

Key Facts

  • Revenue declined to $56.8 million in 2025 from $183.1 million in 2024, primarily due to the absence of one-time collaboration revenue from Bristol Myers Squibb.
  • Net loss was $230.8 million in 2025 compared to a net profit of $17.9 million in 2024.
  • Cash and financial assets totaled $551.4 million as of December 31, 2025, following a $125 million public offering, supporting operations into 2028.
  • Phase 3 SUPRAME trial for anzu-cel in melanoma remains on track with interim and final analyses expected in 2026, BLA submission in 1H 2027, and commercial launch in 2H 2027.
  • Multiple clinical data updates expected in 2026 for IMA203CD8 (ovarian cancer) and IMA402 (melanoma, gynecologic cancers), with combination trials planned.

Financial Impact

Revenue down $126.3 million YoY; net loss widened by $248.7 million; R&D spend increased to $216.0 million from $174.0 million.

revenuenet lossr_d_expensecash_position

Risk Factors

  • High cash burn rate with R&D and G&A expenses increasing, though offset by strong cash reserves.
  • Clinical trial delays or negative data in upcoming readouts could impact valuation, particularly for the pivotal SUPRAME trial.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3250021

Track record

23 reports on IMTX

Performance horizon

8 of 14 bullish or bearish reports moved the stock their way by T+5. Best: +22.12% at T+20 after the May 12, 2026 report. 9 of 14 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $6.24 Now $6.17 −1.12% settles Nov 23
  2. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $6.55 Now $6.17 −5.73% settles Nov 23
  3. Nov 10, 20266d ago 6-K Neutral 5/10 No price data
  4. Nov 10, 20266d ago Press Release Neutral 4/10 Entry $6.42 Now $6.17 −3.89% settles Nov 17
  5. Oct 26, 202621d ago 6-K Bullish 5/10 Entry $7.15 to $7.20 Now $6.17 −13.71% ▲ +0.70% +1.96% vs SPY
  6. Oct 24, 202624d ago Press Release Bullish 6/10 Entry $7.15 to $7.20 Now $6.17 −13.71% ▲ +0.70% +1.96% vs SPY
  7. Oct 23, 202624d ago 6-K Bullish 7/10 Entry $7.31 to $7.20 Now $6.17 −15.60% ▼ −1.50% −0.95% vs SPY
  8. Aug 27, 202611w ago Insider Buy Bullish 6/10 Entry $9.45 to $9.56 Now $6.17 −34.71% ▲ +1.16% +1.05% vs SPY
  9. Aug 26, 202611w ago 6-K Bearish 6/10 Entry $9.36 to $9.46 Now $6.17 +34.08% ▼ −1.07% −0.80% vs SPY
  10. Aug 18, 202612w ago 6-K Neutral 6/10 Entry $9.09 to $9.24 Now $6.17 −32.12% ▲ +1.65% +1.85% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens in 6h 41m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 5, 2026